Clinical Trial Update: Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated tiotropium 5 micrograms per day delivered via the Respimat inhaler as add-on therapy for adults with severe persistent asthma over 48 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Spiriva (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2012-09-27